Adaptimmune Therapeutics PLC — Director's Dealing 2023

Nov 1, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Adaptimmune Therapeutics PLC (ADAP)
CIK: 0001621227
Period of Report: 2023-11-01

Reporting Person: Hege Kristen (Director)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to purchase Ordinary Shares	$0.09	2033-11-01	Ordinary Shares (1000000)		Direct

Footnotes

F1: Exercisable as to 250,000 Ordinary Shares on November 1, 2024 and will be exercisable as to the remainder in monthly installments of 31,250 Ordinary Shares on the first of each month from December 1, 2024 through November 1, 2026.

F2: The exercise price was converted from GBP0.07 based on an exchange rate of $U.S. 1.2133 to GBP1.00. The actual exercise price will be the pounds sterling amount.